Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00030124 | Lung | IAC | muscle system process | 71/2061 | 452/18723 | 1.29e-03 | 1.45e-02 | 71 |
GO:00323887 | Lung | IAC | positive regulation of intracellular transport | 37/2061 | 202/18723 | 1.29e-03 | 1.45e-02 | 37 |
GO:00611382 | Lung | IAC | morphogenesis of a branching epithelium | 34/2061 | 182/18723 | 1.41e-03 | 1.54e-02 | 34 |
GO:00467852 | Lung | IAC | microtubule polymerization | 19/2061 | 83/18723 | 1.43e-03 | 1.55e-02 | 19 |
GO:00705073 | Lung | IAC | regulation of microtubule cytoskeleton organization | 29/2061 | 148/18723 | 1.44e-03 | 1.55e-02 | 29 |
GO:00311123 | Lung | IAC | positive regulation of microtubule polymerization or depolymerization | 11/2061 | 37/18723 | 1.58e-03 | 1.66e-02 | 11 |
GO:00082864 | Lung | IAC | insulin receptor signaling pathway | 24/2061 | 116/18723 | 1.66e-03 | 1.74e-02 | 24 |
GO:00902577 | Lung | IAC | regulation of muscle system process | 43/2061 | 252/18723 | 2.35e-03 | 2.28e-02 | 43 |
GO:00380932 | Lung | IAC | Fc receptor signaling pathway | 13/2061 | 50/18723 | 2.38e-03 | 2.30e-02 | 13 |
GO:19054776 | Lung | IAC | positive regulation of protein localization to membrane | 22/2061 | 106/18723 | 2.44e-03 | 2.33e-02 | 22 |
GO:00083615 | Lung | IAC | regulation of cell size | 33/2061 | 181/18723 | 2.47e-03 | 2.33e-02 | 33 |
GO:00511462 | Lung | IAC | striated muscle cell differentiation | 47/2061 | 283/18723 | 2.66e-03 | 2.45e-02 | 47 |
GO:19038298 | Lung | IAC | positive regulation of cellular protein localization | 46/2061 | 276/18723 | 2.74e-03 | 2.50e-02 | 46 |
GO:00066058 | Lung | IAC | protein targeting | 51/2061 | 314/18723 | 2.91e-03 | 2.61e-02 | 51 |
GO:0055001 | Lung | IAC | muscle cell development | 33/2061 | 184/18723 | 3.24e-03 | 2.79e-02 | 33 |
GO:00149102 | Lung | IAC | regulation of smooth muscle cell migration | 19/2061 | 89/18723 | 3.35e-03 | 2.87e-02 | 19 |
GO:0043506 | Lung | IAC | regulation of JUN kinase activity | 14/2061 | 58/18723 | 3.47e-03 | 2.95e-02 | 14 |
GO:00331352 | Lung | IAC | regulation of peptidyl-serine phosphorylation | 27/2061 | 144/18723 | 3.91e-03 | 3.24e-02 | 27 |
GO:00507675 | Lung | IAC | regulation of neurogenesis | 57/2061 | 364/18723 | 3.92e-03 | 3.24e-02 | 57 |
GO:0014909 | Lung | IAC | smooth muscle cell migration | 20/2061 | 97/18723 | 4.05e-03 | 3.31e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK1 | SNV | Missense_Mutation | | c.184N>A | p.Asp62Asn | p.D62N | Q13153 | protein_coding | tolerated(0.38) | benign(0.033) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PAK1 | SNV | Missense_Mutation | | c.1114G>A | p.Glu372Lys | p.E372K | Q13153 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PAK1 | SNV | Missense_Mutation | | c.229N>A | p.Leu77Ile | p.L77I | Q13153 | protein_coding | tolerated(0.41) | benign(0.236) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1593N>C | p.Met531Ile | p.M531I | Q13153 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
PAK1 | SNV | Missense_Mutation | | c.113N>G | p.Ser38Cys | p.S38C | Q13153 | protein_coding | tolerated(0.17) | probably_damaging(0.917) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | insertion | Nonsense_Mutation | novel | c.226_227insGTGCACATGTATATATATGTATGCAAGAATTTTAATTTT | p.Ile75_Ser76insCysAlaHisValTyrIleCysMetGlnGluPheTerPhe | p.I75_S76insCAHVYICMQEF*F | Q13153 | protein_coding | | | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1532C>T | p.Ser511Leu | p.S511L | Q13153 | protein_coding | deleterious(0) | benign(0.135) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.946A>G | p.Ile316Val | p.I316V | Q13153 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.80N>A | p.Gly27Asp | p.G27D | Q13153 | protein_coding | deleterious_low_confidence(0.04) | benign(0.02) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | | c.95N>A | p.Gly32Glu | p.G32E | Q13153 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AZD-1152-HQPA | AZD-1152-HQPA | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TOZASERTIB | TOZASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | MLN-8054 | MLN-8054 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565861 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | RG-1530 | RG-1530 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |